TY - JOUR
T1 - Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images
T2 - A Report from the Children's Oncology Group
AU - Milewski, David
AU - Jung, Hyun
AU - Brown, G. Thomas
AU - Liu, Yanling
AU - Somerville, Ben
AU - Lisle, Curtis
AU - Ladanyi, Marc
AU - Rudzinski, Erin R.
AU - Choo-Wosoba, Hyoyoung
AU - Barkauskas, Donald A.
AU - Lo, Tammy
AU - Hall, David
AU - Linardic, Corinne M.
AU - Wei, Jun S.
AU - Chou, Hsien Chao
AU - Skapek, Stephen X.
AU - Venkatramani, Rajkumar
AU - Bode, Peter K.
AU - Steinberg, Seth M.
AU - Zaki, George
AU - Kuznetsov, Igor B.
AU - Hawkins, Douglas S.
AU - Shern, Jack F.
AU - Collins, Jack
AU - Khan, Javed
N1 - Publisher Copyright:
©2022 The Authors; Published by the American Association for Cancer Research.
PY - 2023/1/17
Y1 - 2023/1/17
N2 - PURPOSE: Rhabdomyosarcoma (RMS) is an aggressive soft-tissue sarcoma, which primarily occurs in children and young adults. We previously reported specific genomic alterations in RMS, which strongly correlated with survival; however, predicting these mutations or high-risk disease at diagnosis remains a significant challenge. In this study, we utilized convolutional neural networks (CNN) to learn histologic features associated with driver mutations and outcome using hematoxylin and eosin (H&E) images of RMS. EXPERIMENTAL DESIGN: Digital whole slide H&E images were collected from clinically annotated diagnostic tumor samples from 321 patients with RMS enrolled in Children's Oncology Group (COG) trials (1998-2017). Patches were extracted and fed into deep learning CNNs to learn features associated with mutations and relative event-free survival risk. The performance of the trained models was evaluated against independent test sample data (n = 136) or holdout test data. RESULTS: The trained CNN could accurately classify alveolar RMS, a high-risk subtype associated with PAX3/7-FOXO1 fusion genes, with an ROC of 0.85 on an independent test dataset. CNN models trained on mutationally-annotated samples identified tumors with RAS pathway with a ROC of 0.67, and high-risk mutations in MYOD1 or TP53 with a ROC of 0.97 and 0.63, respectively. Remarkably, CNN models were superior in predicting event-free and overall survival compared with current molecular-clinical risk stratification. CONCLUSIONS: This study demonstrates that high-risk features, including those associated with certain mutations, can be readily identified at diagnosis using deep learning. CNNs are a powerful tool for diagnostic and prognostic prediction of rhabdomyosarcoma, which will be tested in prospective COG clinical trials.
AB - PURPOSE: Rhabdomyosarcoma (RMS) is an aggressive soft-tissue sarcoma, which primarily occurs in children and young adults. We previously reported specific genomic alterations in RMS, which strongly correlated with survival; however, predicting these mutations or high-risk disease at diagnosis remains a significant challenge. In this study, we utilized convolutional neural networks (CNN) to learn histologic features associated with driver mutations and outcome using hematoxylin and eosin (H&E) images of RMS. EXPERIMENTAL DESIGN: Digital whole slide H&E images were collected from clinically annotated diagnostic tumor samples from 321 patients with RMS enrolled in Children's Oncology Group (COG) trials (1998-2017). Patches were extracted and fed into deep learning CNNs to learn features associated with mutations and relative event-free survival risk. The performance of the trained models was evaluated against independent test sample data (n = 136) or holdout test data. RESULTS: The trained CNN could accurately classify alveolar RMS, a high-risk subtype associated with PAX3/7-FOXO1 fusion genes, with an ROC of 0.85 on an independent test dataset. CNN models trained on mutationally-annotated samples identified tumors with RAS pathway with a ROC of 0.67, and high-risk mutations in MYOD1 or TP53 with a ROC of 0.97 and 0.63, respectively. Remarkably, CNN models were superior in predicting event-free and overall survival compared with current molecular-clinical risk stratification. CONCLUSIONS: This study demonstrates that high-risk features, including those associated with certain mutations, can be readily identified at diagnosis using deep learning. CNNs are a powerful tool for diagnostic and prognostic prediction of rhabdomyosarcoma, which will be tested in prospective COG clinical trials.
UR - http://www.scopus.com/inward/record.url?scp=85146365247&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85146365247&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-22-1663
DO - 10.1158/1078-0432.CCR-22-1663
M3 - Article
C2 - 36346688
AN - SCOPUS:85146365247
SN - 1078-0432
VL - 29
SP - 364
EP - 378
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 2
ER -